2型糖尿病におけるセマグルチドの用量を0.5mgから1.0mgに増加させた際の実際の有効性と安全性

佐藤ら（Wed）はこの問題を研究しました。

www.synapsesocial.com/papers/69d8967d6c1944d70ce07fae — DOI: https://doi.org/10.1007/s13300-026-01864-6

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Once-Weekly Semaglutide Use in Patients with Type 2 Diabetes: Results from the SURE Spain Multicentre, Prospective, Observational Study· 2022 · 22 citations
2. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial· 2019 · 361 citations
3. Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records· 2021 · 326 citations
4. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes· 2021 · 762 citations
5. High Alanine Aminotransferase Is Associated With Decreased Hepatic Insulin Sensitivity and Predicts the Development of Type 2 Diabetes· 2002 · 716 citations